Global sales of cancer drugs are expected to double
‘Cancer is becoming big business in the Bay Area. But the price tag could loom large, too.
Nearly 400 clinical tests of cancer treatments were under way nationwide last year — more than triple the number in 1993. And a quarter of those studies involved Bay Area companies, ranging from Pharmacyclics of Sunnyvale to Palo-Alto based Telik to Kosan Biosciences in Hayward.
The trend is understandable. Genentech, the Bay Area’s biggest biotech player, has built its recent success largely on blockbuster cancer drugs. By 2009, global sales of cancer drugs are expected to double to $55 billion, according to IMS Health, which tracks the pharmaceutical industry.’
Read more at Global sales of cancer drugs are expected to double
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax